Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. G Ortega, M. C Liu, I. D Pavord, G. B Brusselle, J. M. FitzGerald, A. Chetta, L. E Katz, O. N Keene, S. W Yancey, P. Chanez (Research Triangle Park, Baltimore, United States Of America; Oxford, Stockley Park, United Kingdom; Ghent, Belgium; Vancouver, Canada; Parma, Italy; Marseille, France). LATE-BREAKING ABSTRACT: Reduction in exacerbations with mepolizumab in severe eosinophilic asthma: MENSA study. Eur Respir J 2014; 44: Suppl. 58, 2906

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment Year: 2014 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 LATE-BREAKING ABSTRACT: A phase 2a study of benralizumab in adults with COPD Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 LATE-BREAKING ABSTRACT: Anti-interleukin-5 in severe asthma: Blood eosinophilia predicts lung function improvement Source: Annual Congress 2013 –Origins and diagnosis of asthma Year: 2013 LATE-BREAKING ABSTRACT: Is treatment with inhaled corticosteroids in asthma associated with hospitalisations because of pneumonia? Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life Year: 2016 Characteristics of the adult corticosteroid-dependent severe asthma in UBIOPRED consortium Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Evaluation of methotrexate in the treatment of severe asthma Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 LATE-BREAKING ABSTRACT: Safety and efficacy of inhaled mannitol over 12 months in high-risk patients with non-CF bronchiectasis Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors Source: International Congress 2014 – Asthma and COPD management Year: 2014 Use of β-blockers and the risk of asthma exacerbations Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Discordance between asthma control parameters in patients with frequent vs infrequent asthma exacerbations Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 Predictors of exacerbations in asthma Source: International Congress 2015 – Clinical assessment in asthma and COPD Year: 2015 Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis Source: International Congress 2014 – COPD exacerbations Year: 2014 LATE-BREAKING ABSTRACT: Attenuation of allergen-induced asthmatic responses by inhaled GATA-3 specific DNAzyme Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 LATE-BREAKING ABSTRACT: Benralizumab reduces exacerbations in severe, uncontrolled asthma: Results of the phase III CALIMA trial Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016